AP Biosciences continues to expand international clinical research collaboration and foster biopharmaceutical exchange between Taiwan and Australia. APBio invited Dr. Michelle Morris, oncologist at Sunshine Coast University Private Hospital in Australia and Principal Investigator (PI) of the AP402 clinical trial, to Taiwan to deliver a speech at the Taiwan Society for Immunotherapy of Cancer (TSITC) Summer Symposium. Her talk was titled: “AP402 (p95HER2 x 4-1BB), Clinical trial and other novel immune therapies – an Australian perspective.”
The event was opened by Mr. Christopher Lim, Deputy Representative of the Australian Office in Taipei, who highlighted the strong potential for bilateral collaboration in clinical research and the biopharma industry. He emphasized Taiwan's strengths in clinical research and expressed hope for more frequent exchanges between industry and clinical teams to drive multinational cooperation.
In her speech, Dr. Morris presented the therapeutic value and clinical highlights of AP402. AP402 is the world's first bispecific antibody designed to target p95HER2, developed to treat HER2-positive breast cancer resistant to trastuzumab. The antibody activates both NK and T cell immune responses while promoting p95HER2 internalization. Potential indications include relapsed or refractory HER2-positive breast cancer, gastric cancer, ovarian cancer, and cervical cancer. AP402 is currently in an ongoing Phase I/II clinical trial in Australia.
Beyond clinical trial progress, Dr. Morris also shared key challenges in early-stage immunotherapy development, including patient selection, dose design, and clinical management. She further discussed strategies to ensure that novel therapies are delivered safely and effectively to the right patients.
With the global cancer immunotherapy market continuing to grow rapidly, AP402's differentiated bispecific antibody mechanism positions it with unique competitive advantages. Market research estimates that the global HER2-positive breast cancer treatment market will exceed USD 30 billion by 2030. This Taiwan–Australia collaboration not only strengthens international clinical research networks but also lays the foundation for AP Biosciences' future business development and global licensing partnerships.
*We sincerely appreciate the media coverage and reprints of this news, which help bring greater awareness to AP Biosciences' efforts and achievements in advancing international clinical research and biopharmaceutical collaboration.
